Search results

712 results

Sorted by Relevance . Sort by Date

  1. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention as reported by the IMPACT trial, but delivered by practitioners other than psychiatrists and in other settings, including primary care, to young people aged 12 to 18 years with mild or moderate to severe depression?

    Recommendation ID NG134/4 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief

  2. Can GP practices deliver effective and cost effective condom schemes to reduce STIs?: -Can condom schemes be effective and cost effective in GP practices to reduce STIs? Can they be delivered in ways that are acceptable to GPs and other practice staff? In addition, how can the impact of such schemes be maximised?

    Recommendation ID NG68/5 Question Can GP practices deliver effective and cost effective condom schemes to reduce STIs?: -Can condom schemes

  3. What are the challenges and potential solutions for UK employers and employees in micro-, small- and medium-sized organisations (which may not have easy access to additional services such as employee assistance programmes or occupational health services) in ensuring sickness policy is managed effectively and facilitating return to work?

    Recommendation ID NG146/5 Question What are the challenges and potential solutions for UK employers and employees in micro-, small- and

  4. Children and young people aged 5 to 18 years – brief, group-based, ADHDfocused, parent-training intervention What is the clinical and cost effectiveness, and optimum length, of a brief parent-training intervention for parents and carers of children and young people with attention deficit hyperactivity disorder (ADHD) aged 5 to 18 years?

    Recommendation ID NG87/1 Question Children and young people aged 5 to 18 years – brief, group-based, ADHDfocused, parent-training intervention What

  5. For children and young people with intractable cancer-related pain and pain associated with specific diseases (such as epidermolysis bullosa), what is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on to standard treatment to improve symptoms compared with treatment with standard care?

    Recommendation ID NG144/2 Question For children and young people with intractable cancer-related pain and pain associated with specific